Published in
Oxford University Press (OUP), Annals of Oncology, (29), p. viii106-viii107, 2018
DOI: 10.1093/annonc/mdy272.320
Links
Tools
Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
Journal article published in 2018 by
A. Bardia,
S. Campos-Gomez 
,
S. A. Hurvitz,
Y.-S. Lu,
S.-A. Im,
F. Franke,
L. Chow,
P. Wheatley-Price,
F. Melo Cruz,
J. Alam,
O. Kong,
I. Diaz-Padilla,
M. Miller,
D. Tripathy
,
S. A. Hurvitz,
Y.-S. Lu,
S.-A. Im,
F. Franke,
L. Chow,
P. Wheatley-Price,
F. Melo Cruz,
J. Alam,
O. Kong,
I. Diaz-Padilla,
M. Miller,
D. Tripathy
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 